Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628208 | 0.91 | MAP3K14 (0.33) | MAP3K14NPY5RPIKFYVESCN3ASCN9A | |
| SCHEMBL2628193 | 0.90 | NPY5R (0.32) | MAP3K14NPY5RSCN10ASCN3ASCN9A | |
| SCHEMBL10182555 | 0.87 | NPY5R (0.36) | NPY5RSCN10ASCN3ASCN9A | |
| SCHEMBL2625548 | 0.85 | MAPK13 (0.35) | NPY5RSCN10APIKFYVESCN3ASCN9A | |
| SCHEMBL10182953 | 0.85 | MAP3K14 (0.38) | MAP3K14NPY5RPIKFYVE | |
| SCHEMBL2628220 | 0.83 | NPY5R (0.43) | NPY5RSCN10A | |
| SCHEMBL2628270 | 0.82 | SCN10A (0.36) | NPY5RSCN10ASCN3ASCN9A | |
| SCHEMBL10183501 | 0.82 | NR1I2 (0.31) | MAP3K14NPY5R | |
| SCHEMBL2625672 | 0.81 | NPY5R (0.31) | NPY5RSCN10A | |
| SCHEMBL13294213 | 0.79 | MAPK13 (0.37) | SCN10ASCN3ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245027-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2009102633-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | MAP3K14 3942/4885NPY5R 4728/4885SCN10A 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.